Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of Three CYP2C19 Gene Variants by MassARRAY and Point of Care Techniques: Experience from a Czech Centre.

Archivum immunologiae et therapiae experimentalis - 1 Dec 2016

Petrek Martin, Kocourkova Lenka, Zizkova Veronika, Nosek Zdenek, Taborsky Milos, Petrkova Jana

Abstract excerpt

Distribution of cytochrome P450 2C19 enzyme gene (CYP2C19) variants affecting metabolism of clopidogrel was determined in 526 Czech patients after percutaneous coronary intervention using MassARRAY genotyping and compared to distribution in other populations of European descent. Fifty-three (10%) patients underwent parallel determination of CYP2C19 genotypes from buccal swabs by a point of care technique with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clopidogrel
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Czech Republic

Share to Percutaneous Coronary Intervention

Share to Pharmacogenetics

Share to Platelet Aggregation Inhibitors

Share to Point-of-Care Systems

Share to Ticlopidine

Source

Identifiers

PMID: 28083610
DOI: 10.1007/s00005-016-0440-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of Three CYP2C19 Gene Variants by MassARRAY and Point of Care Techniques: Experience from a Czech Centre.PMID 28083610Read ↗

Genotyping genetic variants of CYP2C19 for precision antiplatelet dosing: state of the art and future perspectives.Semantic proximity Read ↗

Point-Counterpoint: CYP2C19 Genotyping for Clopidogrel.Semantic proximity Read ↗

Comparative analysis of point-of-care bedside cyp2c19-testing guided anti-platelet therapy versus conventional therapies for cardiovascular diseases: a systematic review and meta-analysis.Semantic proximity Read ↗

Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery disease.Semantic proximity Read ↗

Evaluation of a CYP2C19 genotype panel on the GenMark eSensor® platform and the comparison to the Autogenomics Infiniti™ and Luminex CYP2C19 panels.Semantic proximity Read ↗

Comparison of a rapid point-of-care and two laboratory-based CYP2C19*2 genotyping assays for personalisation of antiplatelet therapy.Semantic proximity Read ↗

Point of care CYP2C19 genotyping after percutaneous coronary intervention.Semantic proximity Read ↗

Development and Validation of a Rapid Point-of-Care CYP2C19 Genotyping PlatformSemantic proximity Read ↗

Rapid and portable, lab-on-chip, point-of-care genotyping for evaluating clopidogrel metabolism.Semantic proximity Read ↗

Clopidogrel and CYP2C19 testing: ready for clinical prime time?Semantic proximity Read ↗

Establishment of a CYP2C19 genotyping assay for clinical use.Semantic proximity Read ↗

Development of a routine bedside CYP2C19 genotype assessment program for antiplatelet therapy guidance in a community hospital catheterization laboratory.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.